Gene News and Research

Latest Gene News and Research

Grand Challenges Explorations projects receive new grants for tuberculosis research

Weill Cornell Medical College announced today that it was awarded two $100,000 grants from the Bill & Melinda Gates Foundation as part of the next phase of Grand Challenges Explorations, an initiative to encourage bold and unconventional ideas for global health.

10 Nov 2010

Immunologix partners with Genscript to develop human antibody therapeutics

Immunologix, Inc, a Charleston, SC biotechnology company and a leader in fully human therapeutic antibodies for a variety of diseases and GenScript, a contract research organization (CRO) based in Piscataway, NJ and the industry leader in bio-reagent services, assay development & screening, lead optimization, and antibody drug development, announced today that the companies have formed a strategic partnership to offer a complete platform for producing human antibody therapeutics.

10 Nov 2010

Iris BioTechnologies awarded $245,000 grant under QTDP Program

Iris BioTechnologies Inc., a life sciences company focused on providing patients, doctors, and clinicians with improved methods of identifying effective treatment solutions, and recipient of the Frost and Sullivan 2008 Technology Innovation Award in Pharmacogenomics, is pleased to announce that the company has been awarded $245,000, the maximum amount given for a grant under the US Qualifying Therapeutic Discovery Project (QTDP) Program.

10 Nov 2010

Research report on current and evolving technologies in drug delivery

The drug delivery market is a rapidly evolving force in the pharmaceutical industry. Within this segment injectables have a significant role to play at present with the increasing use of proteins and peptides.

9 Nov 2010

Research may help develop new therapies for aggressive prostate cancer

A monoclonal antibody targeting a well known cell surface protein inhibited prostate cancer growth and metastasis in an aggressive form of the disease that did not respond to hormone therapy, according to a study by researchers with the UCLA Department of Urology and UCLA's Jonsson Comprehensive Cancer Center.

9 Nov 2010

Innovative method for in-cell gene manipulation

A cross-disciplinary Small Medicine and Advanced Research Translation (SMART) team led by Prof. Dar-Bin Shieh of Institute of Oral Medicine in Medical College at National Cheng Kung University (NCKU), Tainan, Taiwan, has announced a breakthrough in the precision in-cell gene scission at pre-designed sequence sites using Artificial Targeting Light Activated Nano Scissors (ATLANS) and a custom build photonic device.

9 Nov 2010

Blood 'metabolomics' study uncovers liver, heart, and kidney toxicity in healthy smokers

Examining the blood "metabolomics" profile of smokers immediately after they had a cigarette revealed activation of pathways involved in cell death, inflammation, and other forms of systemic damage, say researchers at Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center.

9 Nov 2010

Researchers examine impact of gene mutation on Salmonella bacterium growth rate

Most mutations in the genes of the Salmonella bacterium have a surprisingly small negative impact on bacterial fitness. And this is the case regardless whether they lead to changes in the bacterial proteins or not.

9 Nov 2010

Study explains link between morbid obesity and metabolic syndrome

Scientists have found that the fat cells and tissues of morbidly obese people and animals can reach a limit in their ability to store fat appropriately. Beyond this limit several biological processes conspire to prevent further expansion of fat tissue and in the process may trigger other health problems.

9 Nov 2010

New approach to treat castration resistant prostate cancer

9 Nov 2010

Genetic region linked to survival in patients with advanced bowel cancer

Scientists have discovered a genetic region linked to survival in patients with advanced bowel cancer, according to a study being presented at the National Cancer Research Institute (NCRI) Cancer Conference today (Tuesday).

9 Nov 2010

Chemotherapy for breast cancer does more harm than good

A fundamental principle of medicine is: "first, do no harm." However, for doctors who treat breast cancer, this is easier said than done. Every year, almost 22,000 Canadian women are diagnosed with breast cancer - their treatment usually involves surgery to remove a tumour and then chemotherapy to reduce the risk of cancer returning.

9 Nov 2010

Study discovers role of Vav1 oncogene in several cancers

Researchers at the Hebrew University of Jerusalem have discovered that Vav1 - an oncogene (cancer-causing gene) found in recent years to be one of the factors in tumorous tissue growth -- plays a wider role in several types of cancer than had previously been thought. The discovery has implications for further concentration on targeting this gene in cancer research.

9 Nov 2010

Study confirms defect in sweat gland function as disease biomarker for XLHED

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced key findings of a study exploring novel approaches to the assessment of sweat function in males with XLHED. Affected individuals lack a normal sweat response, placing them at life-long risk for clinically-significant hyperthermia.

9 Nov 2010

New COLD-PCR technology to detect EGFR gene mutation

Transgenomic, Inc. today announced completion of a development study of several new assays to detect genetic mutations using the Company's proprietary Co-amplification at Lower Denaturing Temperature PCR (COLD-PCR) technology in the Epidermal Growth Factor Receptor (EGFR) gene.

8 Nov 2010

Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease

Raptor Pharmaceutical Corp., today announced that the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington's Disease. The Phase 2 clinical trial is being conducted under a previously announced collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), which has commenced enrolling patients at eight clinical sites throughout France.

8 Nov 2010

FDA authorizes Athersys' MultiStem Phase II clinical trial for ulcerative colitis

Athersys, Inc. announced today that the U.S. Food and Drug Administration (FDA) has authorized commencement of a Phase II clinical trial evaluating the safety and efficacy of administration of MultiStem, Athersys' allogeneic investigational cell therapy product, for the potential treatment of ulcerative colitis.

8 Nov 2010

Study suggests bacterial products contribute to autoimmune diseases

Researchers are using 21st century technologies to investigate the century old hypothesis that certain autoimmune diseases, including rheumatoid arthritis, are caused by bacteria living in the human body and will present their initial data this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Research findings on RGL2 protein can lead to new therapeutic target for pancreatic cancer

One of the most frustrating problems faced by doctors who treat pancreatic cancer is the lack of effective therapeutic options. More than 38,000 people in the United States die of the disease each year, and new drugs and treatments are desperately needed.

8 Nov 2010

UC researchers receive four-year grant to study mechanism of malarial parasite replication in RBCs

Today, about half the world's population lives in areas at risk of malaria transmission. The disease is transmitted to humans through bites from mosquitoes, and each year causes hundreds of thousands of deaths worldwide, with about 1,500 of these in the United States.

8 Nov 2010

Gene News and Research

Latest Gene News and Research

Grand Challenges Explorations projects receive new grants for tuberculosis research

Immunologix partners with Genscript to develop human antibody therapeutics

Iris BioTechnologies awarded $245,000 grant under QTDP Program

Research report on current and evolving technologies in drug delivery

Research may help develop new therapies for aggressive prostate cancer

Innovative method for in-cell gene manipulation

Blood 'metabolomics' study uncovers liver, heart, and kidney toxicity in healthy smokers

Researchers examine impact of gene mutation on Salmonella bacterium growth rate

Study explains link between morbid obesity and metabolic syndrome

New approach to treat castration resistant prostate cancer

Genetic region linked to survival in patients with advanced bowel cancer

Chemotherapy for breast cancer does more harm than good

Study discovers role of Vav1 oncogene in several cancers

Study confirms defect in sweat gland function as disease biomarker for XLHED

New COLD-PCR technology to detect EGFR gene mutation

Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease

FDA authorizes Athersys' MultiStem Phase II clinical trial for ulcerative colitis

Study suggests bacterial products contribute to autoimmune diseases

Research findings on RGL2 protein can lead to new therapeutic target for pancreatic cancer

UC researchers receive four-year grant to study mechanism of malarial parasite replication in RBCs

eBook: Using iPSCs models for human disease research and drug discovery eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation